VerastemVSTM
VSTM
About: Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Employees: 78
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
322% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 9
151% more call options, than puts
Call options by funds: $414K | Put options by funds: $165K
120% more capital invested
Capital invested by funds: $79.5M [Q3] → $175M (+$95.6M) [Q4]
100% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 14
18% more funds holding
Funds holding: 76 [Q3] → 90 (+14) [Q4]
10.0% more ownership
Funds ownership: 66.08% [Q3] → 76.08% (+10.0%) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
7%
upside
Avg. target
$12.20
63%
upside
High target
$15
100%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Jefferies Kelly Shi 27% 1-year accuracy 3 / 11 met price target | 100%upside $15 | Buy Initiated | 10 Apr 2025 |
Mizuho Mara Goldstein 100% 1-year accuracy 2 / 2 met price target | 7%upside $8 | Outperform Maintained | 9 Apr 2025 |
Guggenheim Michael Schmidt 43% 1-year accuracy 16 / 37 met price target | 87%upside $14 | Buy Maintained | 24 Mar 2025 |
HC Wainwright & Co. Sean Lee 57% 1-year accuracy 17 / 30 met price target | 34%upside $10 | Buy Maintained | 24 Mar 2025 |
RBC Capital Gregory Renza 29% 1-year accuracy 22 / 75 met price target | 87%upside $14 | Outperform Maintained | 21 Mar 2025 |
Financial journalist opinion
Based on 5 articles about VSTM published over the past 30 days
Neutral
Business Wire
5 days ago
Verastem Oncology Announces $75 million Private Placement
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $24 million of shares of its common stock at a price of $7.00 per share and, in lieu of common stock to certain investors, $51 million of pre-funded warrants.
Neutral
Business Wire
1 week ago
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor for clinical evaluation. The Company expects to initiate a Phase 1/2a study in mid-2025 with plans for multiple expansion cohorts, including combinations, i.
Positive
Zacks Investment Research
2 weeks ago
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
Positive
Seeking Alpha
2 weeks ago
Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination
Verastem, Inc.'s priority review PDUFA date of avutometinib + defactinib for treatment of patients with recurrent LGSOC is expected June 30th of 2025; At this time, no FDA advisory committee to be held. The global Non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; KRAS G12C variant is the most common KRAS mutation, accounting for 13% of NSCLC cases. Data from phase 1/2 RAMP-203 study, using avutometinib + LUMAKRAS with or without defacinib to treat patients with KRAS G12C mutant NSCLC, is expected to be presented 2nd half of 2025.
Neutral
Business Wire
3 weeks ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 164,500 shares of its common stock to fourteen new employees and the grant of 83,333 restricted stock units to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 100.9% in Verastem (VSTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
Business Wire
1 month ago
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 to be held on April 25-30 in Chicago, Illinois. These presentations will highlight clinical and preclinical data from the Company's development programs, including VS-7375 (GFH375), an oral KRAS.
Neutral
Business Wire
1 month ago
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2024, and highlighted recent progress. “In 2024, we made tremendous progress across our pipeline programs, most notably the NDA acceptance of our novel-novel combination of avutometinib plus defactinib for Priority Review under the accelerated approval pathway f.
Neutral
Business Wire
2 months ago
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple oral and poster presentations, including an oral presentation of additional analyses from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) trial evaluating the investigational combination of avutometinib plus defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC), at the So.
Neutral
Business Wire
3 months ago
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025, at 1:00 pm EST. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company's website at www.v.
Charts implemented using Lightweight Charts™